This comes back to one of our challenges. I would always like it to be the case that we could have a screening programme that was effective in terms of the value that we get from it, in terms of money and also the outcomes and helping us to identify people early. But part of our difficulty in this area is that there isn't a full understanding of what causes neuroendocrine tumours. As with every area, where we look to have a screening programme we look for genuine scientific evidence. We all like to be evidence-led, not dogma-led, on this issue about what we should do. So, if there is an evidence-led process and there is an appropriate screening programme for individuals who are at greater risk, then we will of course look at that seriously, and as with other things, look to implement it here in Wales.